Semaglutide · Pep IQ

Origin & Background

The drug that changed everything

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk — a synthetic analogue of human GLP-1 modified with a C18 fatty acid chain that enables albumin binding, extending its half-life to approximately 7 days and allowing once-weekly dosing. It was first approved by the FDA in December 2017 as Ozempic for type 2 diabetes. The higher-dose weight management formulation (2.4mg) was approved in June 2021 as Wegovy.

The STEP-1 trial (2021) changed the conversation: 68 weeks of semaglutide 2.4mg produced average weight loss of 14.9% of body weight in people with obesity — an effect size previously only achievable with bariatric surgery. The SELECT trial (2023) then demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in people with cardiovascular disease and obesity but without diabetes — leading to FDA approval of a cardiovascular risk reduction indication for Wegovy in March 2024.

An oral formulation (Rybelsus) is approved for type 2 diabetes, though its bioavailability is lower than injectable. Semaglutide has become one of the most prescribed drugs in history, with over 9 million monthly prescriptions in the US by mid-2025. The drug has also been investigated — with promising results — for Alzheimer's disease, addiction, kidney disease, liver disease (MASH), sleep apnoea, and heart failure.

The SELECT finding: The cardiovascular benefit from semaglutide emerged before significant weight loss and persisted in subgroups with modest weight reduction — suggesting mechanisms beyond caloric deficit, including direct anti-inflammatory effects and GLP-1 receptor activation in cardiovascular tissue. This was the finding that elevated semaglutide from a weight drug to a cardiovascular drug.

Science & Mechanism

GLP-1 — the gut-brain axis

Mechanism of Action

GLP-1R agonism in the hypothalamus: Semaglutide activates GLP-1 receptors in the arcuate nucleus and other hypothalamic regions, reducing hunger signals and increasing satiety. This is the primary appetite-suppression mechanism — food becomes less rewarding and portion sizes naturally decrease.

Gastric emptying slowing: GLP-1R activation delays gastric emptying, prolonging the feeling of fullness after eating and reducing post-meal blood glucose spikes. This contributes to both weight loss and glycaemic control.

Pancreatic insulin regulation: Glucose-dependent stimulation of insulin secretion and suppression of glucagon — the mechanism behind its type 2 diabetes efficacy. Does not cause hypoglycaemia when used alone because the insulin effect is glucose-dependent.

Cardiovascular effects: GLP-1 receptors in the heart and vasculature mediate direct cardioprotective effects — reduced inflammation, improved endothelial function, and cardiac protection independent of weight loss. Explains the SELECT cardiovascular benefit.

Neuroprotective / addiction signals: GLP-1 receptors in the brainstem and mesolimbic system may modulate dopamine reward pathways — potentially explaining emerging evidence for benefit in addiction, Alzheimer's, and other neurological applications.

Community Voices

What people report

Patient ReportNot research evidence · Individual experience

"The 'food noise' disappeared. I'd spent 20 years thinking about food constantly — planning the next meal while eating the current one. Within two weeks of Wegovy that obsession just... stopped. The weight came off but the silence in my head was the bigger change."

Female, 42, using Wegovy 2.4mg. The "food noise" description has become one of the most widely reported and most clinically significant subjective effects — reflecting the suppression of hypothalamic reward signalling around food. Many patients describe this as the first time they have experienced a normal relationship with eating.

Patient ReportNot research evidence · Individual experience

"Down 22kg in 8 months. The muscle loss is real though — I wish someone had told me about resistance training and protein intake before I started. I've had to backtrack and rebuild. The drug did its job but the protocol guidance was lacking."

Male, 51, Ozempic off-label for weight. The muscle loss issue is the most important under-discussed aspect of GLP-1 weight loss — studies suggest 25–40% of weight lost may be lean mass without concurrent resistance training and adequate protein. This is the most critical synergy point for the entire GLP-1 drug class.

Benefits & Evidence

What the data shows

⚖️

Weight loss — clinically significant

STEP-1 trial: 14.9% average body weight loss at 68 weeks with semaglutide 2.4mg vs 2.4% placebo. 50% of participants lost more than 15% of body weight. Weight regain occurs rapidly after stopping — maintenance therapy is required. The most effective non-surgical weight loss intervention ever approved.

● Strong — multiple Phase III RCTs

🫀

Cardiovascular risk reduction

SELECT trial (n=17,604): 20% relative risk reduction in major adverse cardiovascular events over 34 months in people with CVD and obesity without diabetes. FDA approved this indication in March 2024 — the first obesity drug approved for CV risk reduction. Effect independent of weight loss degree.

● Strong — landmark RCT · FDA approved

🩸

Type 2 diabetes glycaemic control

SUSTAIN programme: HbA1c reductions of 1.0–1.8% alongside weight loss. Superior to most other diabetes medications including older GLP-1 agonists. Ozempic approved 2017, established as a first-line T2D agent in major guidelines.

● Strong — multiple RCTs · FDA approved

🧠

Neurological — addiction, Alzheimer's (emerging)

Observational data shows reduced alcohol and drug cravings. A 2024 placebo-controlled trial showed semaglutide reduced alcohol consumption by 40%. Phase III Alzheimer's trials ongoing with positive signals from observational studies. Genuinely exciting but not yet established.

● Emerging — trials ongoing

💤

Sleep apnoea

SURMOUNT-OSA trial (2024): semaglutide reduced obstructive sleep apnoea severity by ~20 events/hour — a clinically meaningful improvement. FDA approved tirzepatide for sleep apnoea in 2024; semaglutide applications ongoing.

● Moderate — Phase III data

Safety First

Risks & considerations

Moderate

Nausea, vomiting, diarrhoea — the most common class effect. Occurs in 40–50% of users, typically during dose escalation. Usually improves after 4–8 weeks at a stable dose. Managed by slow titration.

Moderate

Muscle loss — studies suggest 25–40% of weight lost may be lean mass without resistance training. This is not mentioned prominently enough in prescribing practice. Non-negotiable requirement: resistance training + adequate protein during any GLP-1 protocol.

Moderate

Nutrient deficiencies — reduced appetite means reduced nutrient intake. B12 (impaired gastric absorption), calcium, iron and vitamin D are the most common deficiencies. Supplementation is recommended.

Serious

Pancreatitis risk — rare but serious. History of pancreatitis is a relative contraindication. Severe abdominal pain during treatment warrants immediate medical evaluation.

Serious

Thyroid C-cell tumours (rodent data) — medullary thyroid cancer observed in rodents at high doses. No confirmed human cases, but contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2.

Serious

Rapid weight regain on stopping — most users regain the majority of lost weight within 1–2 years of cessation. This should be framed as a chronic medication, not a course of treatment.

⚠ Key Warnings

Resistance training and 1.2–1.6g/kg protein daily is not optional — it is the most important co-intervention to prevent muscle wasting during GLP-1 weight loss.

Contraindicated in personal or family history of medullary thyroid carcinoma or MEN type 2.

Not a short-term intervention — weight regain is near-universal after stopping. The conversation before starting must include long-term plans.

Compounded semaglutide was widely available during US drug shortages but the FDA has restricted this as the shortage resolved. Verify legal status in your jurisdiction.

Synergy Stack

Nutrients, Supplements & Exercise

Semaglutide produces powerful appetite suppression and weight loss — but the biggest risk is losing muscle alongside fat. The entire synergy stack for semaglutide is focused on preserving lean mass and preventing the nutrient deficiencies that reduced appetite creates.

💊 Nutrients & Supplements

Protein (1.4–1.8g/kg/day)

Priority at every meal — leucine-rich sources

Strong evidence

The most critical intervention. GLP-1 weight loss includes lean mass — studies show 25–40% of weight lost can be muscle without adequate protein. Leucine-rich sources (whey, eggs, chicken, fish) are most anabolic. Spread across 4+ small meals to maximise muscle protein synthesis despite reduced appetite.

Creatine monohydrate

5g/day — any time

Strong evidence

The most evidence-backed supplement for preserving muscle during caloric restriction. Works through phosphocreatine replenishment and osmotic cell volumisation. Combine with resistance training for maximum lean mass preservation during weight loss.

Vitamin B12 (methylcobalamin)

1000mcg sublingual daily

Strong evidence

GLP-1R presence in the stomach slows gastric emptying — this can impair B12 intrinsic factor-dependent absorption. Sublingual bypasses gastric absorption entirely. B12 deficiency causes neurological symptoms that can be misattributed to other causes.

Vitamin D3 + K2

2000–4000 IU D3 with K2

Moderate evidence

Reduced food intake means reduced vitamin D intake. Rapid weight loss also increases bone resorption risk. D3 and K2 together protect bone mineral density during the weight loss phase.

Magnesium glycinate

300–400mg/day

Moderate evidence

GI side effects deplete magnesium. Also supports muscle function, insulin sensitivity, and sleep quality. Glycinate form is best tolerated alongside GI-stressed GLP-1 therapy.

🏃 Exercise & Lifestyle

Resistance training — non-negotiable

3–4x/week compound lifts. Without resistance training, up to 40% of GLP-1 weight loss comes from muscle. Studies show resistance training + adequate protein reduces muscle loss to under 10% of total weight lost. This is the most important lifestyle addition for anyone on a GLP-1 agent.

Gradual dose escalation

GI side effects (nausea, vomiting) drive early discontinuation. The slowest tolerable titration reduces side effects substantially. If nausea is severe, discuss half-dose extensions with your prescriber — slower escalation is better than stopping.

Protein-first eating pattern

Eat protein before carbohydrates at every meal. GLP-1 reduces total intake — ensuring protein is consumed first means the reduced calories prioritise muscle preservation over carbohydrate storage. A practical and highly effective strategy on a very reduced appetite.

⏱ Timing & Protocol Notes

Semaglutide injected once weekly — day of week is flexible but consistency matters. Start at 0.25mg/week for 4 weeks, titrate slowly toward target dose. Protein and creatine daily. B12 away from food. Resistance training on non-injection days is fine. Plan for this to be long-term — exit strategy (maintaining with diet/exercise or continuing medication) should be discussed before starting.

Disclaimer: These recommendations are educational. Semaglutide requires prescription and physician supervision. The resistance training and protein requirements are not optional — they are essential safety co-interventions.

Honest Assessment

Editor's summary

Semaglutide is in a different category from every other peptide in this book. The evidence base is vast, the regulatory scrutiny is the highest in medicine, and the clinical effects are profound — not marginal. For people with obesity and cardiovascular disease, the SELECT data has made this a genuinely disease-modifying treatment, not just a weight loss drug.

The honest cautions are equally important. The muscle loss problem is under-discussed in prescribing practice and over the next decade it may emerge as a significant public health concern as millions of people lose substantial lean mass. The rapid weight regain after stopping is built into the drug's mechanism and must be part of every conversation before prescribing. The long-term thyroid and pancreatic effects remain monitored questions rather than established risks — but they warrant ongoing vigilance.

For the book's core audience — biohackers and wellness community — semaglutide is the most consequential approved peptide available. The key is ensuring it is used with the resistance training and nutrition support that preserves the muscle mass its weight loss would otherwise sacrifice.

Verdict

"The most transformative weight loss drug in history and a proven cardiovascular treatment. The evidence is exceptional. The clinical reality requires commitment: resistance training, protein, monitoring, and a long-term perspective. Not a course — a chronic medication for a chronic condition."